Omeros | OMER - Equity Capital And Reserves


Omeros reported $-228.68M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 408.21M 17.88M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Immunic USD 151.23M 157.91M Mar/2026
Insmed USD 757.49M 52.64M Jun/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
MacroGenics USD 42.87M 21.68M Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 671.98M 18.08M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026